Tiziana Life Sciences says foralumab shows promise in Alzheimer's treatment
Portfolio Pulse from
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its investigational drug, intranasal foralumab, is showing potential in treating Alzheimer's disease. The drug is part of an expanded access program, with the first patient having received the therapy.
February 11, 2025 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences' intranasal foralumab shows promise in treating Alzheimer's, with the first patient receiving therapy under an expanded access program.
The news highlights a significant development for Tiziana Life Sciences as it positions its drug, foralumab, as a potential treatment for Alzheimer's, a disease with few options. This could lead to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100